HC Wainwright Has Bullish Outlook for PTGX FY2026 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Protagonist Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $4.61 per share for the year, up from their previous forecast of $4.00. HC Wainwright has a “Buy” rating and a $221.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $4.59 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at $0.31 EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at $0.67 EPS, FY2029 earnings at $7.60 EPS and FY2030 earnings at $7.78 EPS.

Several other research analysts have also recently commented on the company. Johnson Rice set a $165.00 price target on Protagonist Therapeutics in a research note on Friday, July 17th. Weiss Ratings upgraded Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. The Goldman Sachs Group upgraded Protagonist Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Wall Street Zen raised Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Leerink Partners assumed coverage on Protagonist Therapeutics in a research report on Monday, October 12th. They issued an “outperform” rating and a $190.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $166.67.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $135.90 on Tuesday. Protagonist Therapeutics has a 1 year low of $77.00 and a 1 year high of $160.81. The firm has a market cap of $8.79 billion, a price-to-earnings ratio of 28.79 and a beta of 1.21. The stock’s 50-day simple moving average is $141.35 and its 200-day simple moving average is $118.09.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. The company had revenue of $274.41 million during the quarter, compared to analysts’ expectations of $238.49 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Protagonist Therapeutics during the second quarter valued at $162,357,000. Johnson & Johnson bought a new position in shares of Protagonist Therapeutics during the second quarter worth about $300,220,852. Hsbc Holdings PLC increased its holdings in shares of Protagonist Therapeutics by 1,260.9% in the 2nd quarter. Hsbc Holdings PLC now owns 25,952 shares of the company’s stock worth $3,198,000 after acquiring an additional 24,045 shares during the period. Deutsche Bank AG acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth about $17,387,000. Finally, Stempoint Capital LP lifted its position in Protagonist Therapeutics by 22.1% in the 1st quarter. Stempoint Capital LP now owns 72,577 shares of the company’s stock valued at $7,650,000 after purchasing an additional 13,147 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Activity

In other news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the transaction, the chief executive officer owned 522,968 shares of the company’s stock, valued at approximately $75,359,688.80. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 183,629 shares of company stock valued at $26,552,987 in the last three months. Insiders own 5.19% of the company’s stock.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: HC Wainwright raised estimates across several periods: FY2026 EPS to $4.61 from $4.00; FY2027 loss per share to $0.98 from $2.80; and FY2028 to profit of $0.67 from a projected loss of $2.45. Longer-term forecasts rose sharply, with FY2029 EPS revised to $7.60 from $0.12 and FY2030 to $7.78 from $1.46. The firm also now expects Q4 2027 EPS of $0.31, versus its prior loss estimate of $0.15.
• Positive Sentiment: HC Wainwright maintains a Buy rating and a $221 price target; a separate report says the target was raised to $221. Article: Protagonist Therapeutics Price Target Raised to $221.00

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.